Enquirer Consulting Group

Reachable Buyer Map

Prepared for Alejandro Villaveces · HealthGenAI · August 2026
From the outside, HealthGenAI reads as network-led: a studio model runs on introductions, and introductions reach the clinics, partners and investors already inside the circle. That is a fast channel and a closed one. This map is what sits outside it. The segments that buy fertility and clinical AI across the Gulf, the wider Middle East and North Africa, and Latin America, who signs inside each one, and roughly how many units sit there.
Fertility clinics across the Gulf
Your closest market and the one where private ownership is most common, so the person who validates the technology and the person who signs for it are usually two doors apart rather than two countries apart.
Who signs: laboratory director, senior embryologist, medical director, clinic owner or managing partner.
150 to 220
licensed assisted reproduction units across the six Gulf states; a small number of groups own several of them
Fertility clinics across the wider Middle East and North Africa
Higher unit counts and higher case volumes than the Gulf, with more units run by their founding clinician. Cost sensitivity is real here, and so is the competitive pressure on success rates.
Who signs: founding clinician and owner, laboratory director, embryology lead.
450 to 650
assisted reproduction units across Egypt, Turkey, the Levant and North Africa; registration standards vary by country, so the true figure sits inside this band rather than at a point
Fertility clinics across Latin America
A regionally networked market where clinics publish and compare outcomes with each other, which means a credible result travels between accounts faster here than anywhere else on this map.
Who signs: medical director, laboratory director, group chief executive.
180 to 240
registered assisted reproduction units across Latin America; the unregistered layer below them is not publicly countable
Private hospital and clinic groups
The buyer above the clinic. One decision covers several sites, and the technology question is framed as portfolio and differentiation rather than as a single laboratory purchase.
Who signs: group chief medical officer, chief innovation or digital officer, head of clinical services, procurement director.
90 to 140
multi-site private healthcare operators across the Gulf and the wider region
Pharma and device companies in fertility and women's health
They already sell into every clinic on this map and they carry commercial teams in these regions. For a studio that is a partnership and distribution conversation rather than a unit sale.
Who signs: regional commercial or market access lead, head of digital health, business development and partnering.
30 to 50
companies with fertility or women's health portfolios and a commercial presence across these regions
Government and payer health programs
The slowest cycle here and the largest single decision. Not a segment to count, a list to name and work patiently.
Who signs: program director, health ministry digital lead, national fund or payer procurement.
A short named list
national and emirate-level health programs are named individually rather than counted, and each one is a multi-year cycle
Health AI founders and their investors
Not a customer segment at all. For a studio the deal flow side is its own reach problem, with its own list and its own message, and it is usually the one left to inbound.
Who signs: founder and chief executive at early stage health AI companies, principals at regional venture funds and family offices.
A separate list
sourcing reach is a distinct audience from buying reach, and the two lists share almost no names

Where the openings are

1
Every clinic sale needs two signatures. The laboratory director validates the method and the owner or medical director signs for it. Reaching one and not the other is where this category stalls, because a convinced laboratory with no commercial sponsor produces a long pilot and no purchase order. Naming both seats inside the same unit is the whole difference.
2
Group ownership compresses the market at the top. A few dozen multi-site operators account for a large share of the units across the Gulf, so the list that matters most is short enough to work person by person rather than campaign by campaign. That is a research problem, not a volume problem.
3
The clinic is also a marketer. Fertility units compete openly for patients, which means the same named list carries two offers: the laboratory technology, and anything that grows their patient volume. Most companies in this space build a channel for one of those and then rebuild it from scratch for the other.
4
The studio has two reach problems, not one. Buyers sit in the segments above. Deal flow sits with founders and funds, an entirely separate list that shares almost no names with the first. Running both through introductions alone caps each of them at the size of the same network.
Built from public market data covering the Gulf, the wider Middle East and North Africa, and Latin America, counts banded deliberately. Licensing and registration standards differ by country and some units operate without public registration, so these bands describe the countable licensed layer rather than every clinic in the market. It describes the market rather than your business, and there is nothing to buy at the end of it.
ENQUIRER CONSULTING GROUP
enquirerconsulting.com